mTOR-Understanding the Clinical Effects

Transplantation Proceedings

Volumn 40, Issue 10 SUPPL., 2008, Pages

  Contreras, A G ^a   Dormond, O ^a   Edelbauer, M ^a   Calzadilla, K ^a   Hoerning, A ^a   Pal, S ^a   Briscoe, D M ^a  

^a Division of Nephrology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; VASCULOTROPIN;

ALLOGRAFT; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL DISRUPTION; CELL HYPOXIA; CELL LINEAGE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; CHRONIC GRAFT REJECTION; ENDOTHELIUM CELL; GLOMERULUS BASEMENT MEMBRANE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE CELL; NEPHRON; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; GRAFT REJECTION; HUMANS; INFLAMMATION; MAMMALS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57649220175     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.011     Document Type: Article

References (30)

1. Heitman J., Movva N.R., and Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253 (1991) 905
2. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253
3. Loewith R., Jacinto E., Wullschleger S., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10 (2002) 457
4. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471
5. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9
6. Sarbassov D.D., Ali S.M., and Sabatini D.M. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17 (2005) 596
7. Hara K., Maruki Y., Long X., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002) 177
8. Frias M.A., Thoreen C.C., Jaffe J.D., et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16 (2006) 1865
9. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22 (2006) 159
10. Sarbassov D.D., Guertin D.A., Ali S.M., et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098
11. Facchinetti V., Ouyang W., Wei H., et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27 (2008) 1932
12. Brazelton T.R., and Morris R.E. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 8 (1996) 710
13. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35 (2003) 7S
14. Sho M., Samsonov D.V., and Briscoe D.M. Immunologic targets for currently available immunosuppressive agents: what is the optimal approach for children?. Semin Nephrol 21 (2001) 508
15. Zeiser R., Leveson-Gower D.B., Zambricki E.A., et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111 (2008) 453
16. Haxhinasto S., Mathis D., and Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 205 (2008) 565
17. Phung T.L., Ziv K., Dabydeen D., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006) 159
18. Dormond O., Madsen J.C., and Briscoe D.M. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 282 (2007) 23679
19. Contreras A.G., and Briscoe D.M. Every allograft needs a silver lining. J Clin Invest 117 (2007) 3645
20. Reinders M.E., Rabelink T.J., and Briscoe D.M. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 17 (2006) 932
21. Rabelink T.J., Wijewickrama D.C., and de Koning E.J. Peritubular endothelium: the Achilles heel of the kidney?. Kidney Int 72 (2007) 926
22. Vos I.H., and Briscoe D.M. Endothelial injury: cause and effect of alloimmune inflammation. Transpl Infect Dis 4 (2002) 152
23. Aydin Z., van Zonneveld A.J., de Fijter J.W., et al. New horizons in prevention and treatment of ischaemic injury to kidney transplants. Nephrol Dial Transplant 22 (2007) 342
24. Cotran R.S. Inflammation and repair. In: Cotran R.S., Kumar V., and Robbins S.L. (Eds). Pathologic basis of disease (1994), W.B. Saunders, Philadelphia 51
25. Reinders M.E., and Briscoe D.M. Angiogenesis and allograft rejection. Graft 5 (2002) 96
26. Denton M.D., Magee C., Melter M., et al. TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. Transplantation 78 (2004) 1218
27. Tanaka H., Sukhova G.K., and Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb 14 (1994) 734
28. Libby P., and Zhao D.X. Allograft arteriosclerosis and immune-driven angiogenesis. Circulation 107 (2003) 1237
29. Reinders M.E., Fang J.C., Wong W., et al. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation 76 (2003) 224
30. Lemstrom K.B., Krebs R., Nykanen A.I., et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 105 (2002) 2524